ArticleNature communications2026
A single mutation in nonstructural protein 1 is critical for the adaptive evolution of influenza B virus.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Divergent pathogenic mechanisms of influenza A and influenza B viruses.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Influenza B virus (IBV) has circulated in the human population for a long time, yet the evolutionary mechanisms responsible for host adaptation remain poorly understood. Here we show that recent IBV strains exhibit an enhanced ability to evade the innate immune response and an increased replication efficiency compared with earlier strains. Our data indicate that the nonstructural protein 1 (NS1) of recent IBV strains interacts with TUFM and LC3B to induce mitophagy, leading to degradation of MAVS, suppression of interferon production and enhanced viral replication. In contrast, NS1 of earlier strains displays minimal ability to trigger mitophagy-mediated MAVS degradation. Sequence analyses show that, over the past two decades, IBV has acquired a phenylalanine (F)-to-leucine (L) substitution at residue 247 of NS1, altering its interaction with LC3B. A rescued recent IBV strain carrying the NS1-L247F mutation exhibits diminished NS1-LC3B binding, impaired mitophagy, and attenuated replication. Our study shows that adaptive evolution involving a single mutation in NS1 enables mitophagy-mediated innate immune evasion, contributing to IBV adaptation to the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.